Results 81 to 90 of about 300,077 (226)
How I Treat Polycythemia Vera.
Blood, 2019 Since its discovery 125 years ago, polycythemia vera (PV) has been a challenge to the clinicians responsible for its diagnosis and management, and the scientists attempting to define its molecular basis.
J. Spivak
semanticscholar +1 more source
Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation
ACR Open Rheumatology, Volume 8, Issue 6, June 2026.Chronic inflammation, characteristic of many autoimmune diseases, such as rheumatoid arthritis (RA), or myeloproliferative neoplasms (MPNs), is an independent driver of accelerated cardiovascular (CV) risk, primarily through proinflammatory cytokines that induce atherosclerosis and endothelial dysfunction.
Aliki Zavoriti, Pierre Miossec
wiley +1 more source
International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail +7 more
wiley +1 more source
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Haematologica, 2017 Up to 20% of patients with polycythemia vera have karyotypic abnormalities at the time of the initial diagnosis. However, the cytogenetic abnormalities in polycythemia vera have not been well characterized and their prognostic impact is largely unknown ...
Guilin Tang +13 more
doaj +1 more source
JAAD Case Reports, 2019 Sarcoidosis is a chronic multisystem inflammatory disorder characterized by the formation of immune granulomas that may lead to serious, often irreversible, disability and significant disease-associated mortality.1 Current understanding suggests that ...
Jenny J. Wei +4 more
semanticscholar +1 more source
What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson +5 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 6, June 2026.Individuals with Down syndrome have distinctive cancer profiles as compared with the general US population. Healthcare guidelines related to cancer screenings should reflect these unique profiles. ABSTRACT Introduction It is known that individuals with Down syndrome (DS) have a significantly different spectrum of malignancies and neoplasms.
Veronica Fitzpatrick +6 more
wiley +1 more source
Updates in the management of polycythemia vera and essential thrombocythemia
Therapeutic Advances in Hematology, 2019 Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar +1 more source
Polycythemia Vera: New Diagnostic Concept and Its Types
Клиническая онкогематология, 2016 Polycythemia vera (PV) is a clonal Ph-negative myeloproliferative disorder characterized by excessive myeloid proliferation of three hematopoietic cell lineages leading to ineffective myelopoiesis.
Alla Mikhailovna Kovrigina, V. V. Baikov
doaj +1 more source
Clinical Lymphoma, Myeloma & Leukemia, 2019 Approximately half of the patients with polycythemia vera experience substantial symptom burdens. We analyzed data from the ongoing Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices (REVEAL) study to evaluate the
M. Grunwald +10 more
semanticscholar +1 more source